Terminated PHASE1 INTERVENTIONAL 1-arm NCT00652158

A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignancies

Sponsor: Millennium Pharmaceuticals, Inc.

Interventions MLN8054

Updated 6 times since 2017 Last updated: Sep 20, 2013 Started: Apr 30, 2006 Primary completion: Mar 31, 2008 Completion: Apr 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Millennium Pharmaceuticals, Inc.

More terminations from Millennium Pharmaceuticals, Inc.

Other Advanced Malignancies trials with similar outcome

Browse all Advanced Malignancies trials

This PHASE1 trial investigates Advanced Malignancies and is currently terminated or withdrawn. Millennium Pharmaceuticals, Inc. leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1

First recorded

Apr 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Millennium Pharmaceuticals, Inc.

Data source: Millennium Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Barcelona, Spain